4.8 Article

MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin

Journal

CANCER RESEARCH
Volume 76, Issue 12, Pages 3604-3617

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-0879

Keywords

-

Categories

Funding

  1. Cancer Council New South Wales [RG11-01, RG15-16]
  2. National Health and Medical Research Council [510378]
  3. Cancer Institute New South Wales [09CDF217]
  4. Italian Association for Cancer Research (AIRC)

Ask authors/readers for more resources

The RNA-binding protein dyskerin, encoded by the DKC1 gene, functions as a core component of the telomerase holoenzyme as well as ribonuclear protein complexes involved in RNA processing and ribosome biogenesis. The diverse roles of dyskerin across many facets of RNA biology implicate its potential contribution to malignancy. In this study, we examined the expression and function of dyskerin in neuroblastoma. We show that DKC1 mRNA levels were elevated relative to normal cells across a panel of 15 neuroblastoma cell lines, where both N-Myc and c-Myc directly targeted the DKC1 promoter. Upregulation of MYCN was shown to dramatically increase DKC1 expression. In two independent neuroblastoma patient cohorts, high DKC1 expression correlated strongly with poor event-free and overall survival (P < 0.0001), independently of established prognostic factors. RNAi-mediated depletion of dyskerin inhibited neuroblastoma cell proliferation, including cells immortalized via the telomerase-independent ALT mechanism. Furthermore, dyskerin attenuation impaired anchorage-independent proliferation and tumor growth. Overexpression of the telomerase RNA component, hTR, demonstrated that this proliferative impairment was not a consequence of telomerase suppression. Instead, ribosomal stress, evidenced by depletion of small nucleolar RNAs and nuclear dispersal of ribosomal proteins, was the likely cause of the proliferative impairment in dyskerin-depleted cells. Accordingly, dyskerin suppression caused p53-dependent G1 cell-cycle arrest in p53 wild-type cells, and a p53-independent pathway impaired proliferation in cells with p53 dysfunction. Together, our findings highlight dyskerin as a new therapeutic target in neuroblastoma with crucial telomerase-independent functions and broader implications for the spectrum of malignancies driven by MYC family oncogenes. (C) 2016 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

High density lipoprotein nanoparticle as delivery system for radio-sensitising miRNA: An investigation in 2D/3D head and neck cancer models

Pouya Dehghankelishadi, Michelle F. Maritz, Parisa Badiee, Benjamin Thierry

Summary: This study demonstrates the potential of using high-density lipoprotein nanoparticles as a delivery system for radio-sensitising RNA in head and neck cancer cells. The results show enhanced radiation effects and increased apoptosis when miR34a is delivered by HDL nanoparticles.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2022)

Article Oncology

Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma

Janith A. Seneviratne, Daniel R. Carter, Rituparna Mittra, Andrew Gifford, Patrick Y. Kim, Jie-Si Luo, Chelsea Mayoh, Alice Salib, Aldwin S. Rahmanto, Jayne Murray, Ngan C. Cheng, Zsuzsanna Nagy, Qian Wang, Ane Kleynhans, Owen Tan, Selina K. Sutton, Chengyuan Xue, Sylvia A. Chung, Yizhuo Zhang, Chengtao Sun, Li Zhang, Michelle Haber, Murray D. Norris, Jamie I. Fletcher, Tao Liu, Pierre J. Dilda, Philip J. Hogg, Belamy B. Cheung, Glenn M. Marshall

Summary: High expression of mitochondrial adenine nucleotide translocase 2 (SLC25A5/ANT2) predicts poor prognosis and a more malignant phenotype in neuroblastoma. Inhibiting this transporter reduces cell viability in neuroblastoma cells. The histone deacetylase inhibitor suberanilohydroxamic acid (SAHA) is the most effective drug against mutant TP53 neuroblastoma cells. SAHA and PENAO together delay tumor progression in neuroblastoma mouse models.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Multidisciplinary Sciences

Heritable defects in telomere and mitotic function selectively predispose to sarcomas

Mandy L. Ballinger, Swetansu Pattnaik, Piyushkumar A. Mundra, Milita Zaheed, Emma Rath, Peter Priestley, Jonathan Baber, Isabelle Ray-Coquard, Nicholas Isambert, Sylvain Causeret, Winette T. A. van der Graaf, Ajay Puri, Florence Duffaud, Axel Le Cesne, Beatrice Seddon, Coonoor Chandrasekar, Joshua D. Schiffman, Andrew S. Brohl, Paul A. James, Jean-Emmanuel Kurtz, Nicolas Penel, Ola Myklebost, Leonardo A. Meza-Zepeda, Hilda Pickett, Maya Kansara, Nicola Waddell, Olga Kondrashova, John Pearson, Andrew P. Barbour, Shuai Li, Tuong L. Nguyen, Diane Fatkin, Robert M. Graham, Eleni Giannoulatou, Melissa J. Green, Warren Kaplan, Shyamsundar Ravishankar, Joseph Copty, Joseph E. Powell, Edwin Cuppen, Kristel van Eijk, Jan Veldink, Jin-Hee Ahn, Jeong Eun Kim, R. Lor Randall, Kathy Tucker, Ian Judson, Rajiv Sarin, Thomas Ludwig, Emmanuelle Genin, Jean-Francois Deleuze, Michelle Haber, Glenn Marshall, Murray J. Cairns, Jean-Yves Blay, David M. Thomas

Summary: Cancer genetics has focused on epithelial malignancies, but this study explores specific pathways related to sarcomas, rare malignancies derived from embryonic mesoderm. Germline sequencing of sporadic cases and healthy controls reveals two sarcoma-specific pathways involved in mitotic and telomere functions. Centrosome gene variants are linked to specific tumors, while heritable defects in the shelterin complex increase susceptibility to sarcomas, melanomas, and thyroid cancers. These findings highlight the role of heritable defects in mitotic and telomere biology in sarcoma risk.

SCIENCE (2023)

Article Oncology

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities

Claire Xin Sun, Paul Daniel, Gabrielle Bradshaw, Hui Shi, Melissa Loi, Nicole Chew, Sarah Parackal, Vanessa Tsui, Yuqing Liang, Mateusz Koptyra, Shazia Adjumain, Christie Sun, Wai Chin Chong, Dasun Fernando, Caroline Drinkwater, Motahhareh Tourchi, Dilru Habarakada, Dhanya Sooraj, Diana Carvalho, Phillip B. Storm, Valerie Baubet, Leanne C. Sayles, Elisabet Fernandez, Thy Nguyen, Mia Poerksen, Anh Doan, Duncan E. Crombie, Monty Panday, Nataliya Zhukova, Matthew D. Dun, Louise E. Ludlow, Bryan Day, Brett W. Stringer, Naama Neeman, Jeffrey A. Rubens, Eric H. Raabe, Maria Vinci, Vanessa Tyrrell, Jamie I. Fletcher, Paul G. Ekert, Biljana Dumevska, David S. Ziegler, Maria Tsoli, Nur Farhana Syed Sulaiman, Amos Hong Pheng Loh, Sharon Yin Yee Low, E. Alejandro Sweet-Cordero, Michelle Monje, Adam Resnick, Chris Jones, Peter Downie, Bryan Williams, Joseph Rosenbluh, Daniel Gough, Jason E. Cain, Ron Firestein

Summary: The study establishes a pediatric cancer model resource with 261 cell lines, including 224 representing childhood tumor types. Through multi-omics analysis and genetic screening, specific treatment opportunities and biomarkers in pediatric tumor classes are identified. The findings are of great significance in improving the clinical relevance of pediatric cancer treatment.

CANCER CELL (2023)

Article Cell Biology

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia

Ernest Moles, Christopher B. Howard, Pie Huda, Mawar Karsa, Hannah McCalmont, Kathleen Kimpton, Alastair Duly, Yongjuan Chen, Yizhou Huang, Melinda L. Tursky, David Ma, Sonia Bustamante, Russell Pickford, Patrick Connerty, Sofia Omari, Christopher J. Jolly, Swapna Joshi, Sylvie Shen, John E. Pimanda, Alla Dolnikov, Laurence C. Cheung, Rishi S. Kotecha, Murray D. Norris, Michelle Haber, Charles E. de Bock, Klaartje Somers, Richard B. Lock, Kristofer J. Thurecht, Maria Kavallaris

Summary: High-risk childhood leukemia has a poor prognosis due to treatment failure and toxic side effects. Encapsulation of drugs in liposomal nanocarriers improves biodistribution and tolerability, but lacks selectivity for cancer cells. In this study, bispecific antibodies were generated to target PEGylated liposomal drugs to leukemic cells. These antibodies improved targeting and cytotoxic activity, with minimal harm to normal cells. Targeted delivery using bispecific antibodies enhanced leukemia suppression and extended overall survival, representing a promising platform for improved treatment of high-risk leukemia.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Multidisciplinary Sciences

Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes

Pamela Ajuyah, Chelsea Mayoh, Loretta M. S. Lau, Paulette Barahona, Marie Wong, Hazel Chambers, Fatima Valdes-Mora, Akanksha Senapati, Andrew J. Gifford, Colleen D'Arcy, Jordan R. Hansford, Neevika Manoharan, Wayne Nicholls, Molly M. Williams, Paul J. Wood, Mark J. Cowley, Vanessa Tyrrell, Michelle Haber, Paul G. Ekert, David S. Ziegler, Dong-Anh Khuong-Quang

Summary: This study reports a new subtype of midline gliomas with similar features to DMG but lacking the H3K27M mutation. These tumors have recurrent mutations in ACVR1 or EGFR and high expression of EZHIP. They have a poor prognosis similar to H3K27M DMG and exhibit distinct transcriptome and methylome profiles. The study provides new insights into the mechanism and pathway regulation of these tumors, potentially opening new therapeutic avenues.

SCIENTIFIC REPORTS (2023)

Article Genetics & Heredity

A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

Chelsea Mayoh, Andrew J. Gifford, Rachael Terry, Loretta M. S. Lau, Marie Wong, Padmashree Rao, Tyler Shai-Hee, Federica Saletta, Dong-Anh Khuong-Quang, Vicky Qin, Marion K. Mateos, Deborah Meyran, Katherine E. Miller, Aysen Yuksel, Emily V. A. Mould, Rachel Bowen-James, Dinisha Govender, Akanksha Senapati, Nataliya Zhukova, Natacha Omer, Hetal Dholaria, Frank Alvaro, Heather Tapp, Yonatan Diamond, Luciano Dalla Pozza, Andrew S. Moore, Wayne Nicholls, Nicholas G. Gottardo, Geoffrey McCowage, Jordan R. Hansford, Seong-Lin Khaw, Paul J. Wood, Daniel Catchpoole, Catherine E. Cottrell, Elaine R. Mardis, Glenn M. Marshall, Vanessa Tyrrell, Michelle Haber, David S. Ziegler, Orazio Vittorio, Joseph A. Trapani, Mark J. Cowley, Paul J. Neeson, Paul G. Ekert

Summary: By combining immunohistochemistry, RNA sequencing, and whole-genome sequencing, we identified a novel 15-gene immune signature, IPASS, associated with CD8(+) T-cell infiltration in high-risk paediatric cancers. Using this signature, we estimated that up to 31% of high-risk cancers exhibit infiltrating T-cells. Furthermore, we found that PD-L1 protein expression is poorly correlated with PD-L1 RNA expression, and neoantigen load and TMB are not predictive of T-cell infiltration in paediatric cancers.

GENOME MEDICINE (2023)

Article Multidisciplinary Sciences

Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma

Jordan F. Hastings, Sharissa L. Latham, Alvin Kamili, Madeleine S. Wheatley, Jeremy Z. R. Han, Marie Wong-Erasmus, Monica Phimmachanh, Max Nobis, Chiara Pantarelli, Antonia L. Cadell, Yolande E. I. O'Donnell, King Ho Leong, Sophie Lynn, Fan-Suo Geng, Lujing Cui, Sabrina Yan, Joanna Achinger-Kawecka, Clare Stirzaker, Murray D. Norris, Michelle Haber, Toby N. Trahair, Frank Speleman, Katleen De Preter, Mark J. Cowley, Ozren Bogdanovic, Paul Timpson, Thomas R. Cox, Walter Kolch, Jamie I. Fletcher, Dirk Fey, David R. Croucher

Summary: Gene expression noise promotes stochastic drug resistance in rare cancer cells. However, when integrated across multiple components of an apoptotic signaling network, the influence of noise leads to a higher frequency of chemoresistant neuroblastoma cells. These cells are characterized by JNK impairment and retain a memory of their resistant state even after chemotherapy treatment.

SCIENCE ADVANCES (2023)

Article Oncology

Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives

Claire E. Wakefield, Kate Hetherington, Eden G. Robertson, Mark W. Donoghoe, Jacqueline D. Hunter, Janine Vetsch, Jonathan M. Marron, Katherine M. Tucker, Glenn M. Marshall, Alexander Broom, Michelle Haber, Vanessa Tyrrell, David Malkin, Loretta Lau, Marion K. Mateos, Tracey A. O'Brien, David S. Ziegler

Summary: Parents and patients rarely regretted participating in a childhood cancer precision medicine trial, even when their hopes were not fulfilled. Most participants found the trial beneficial and expressed high satisfaction.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Chelsea Mayoh, Jie Mao, Jinhan Xie, Gabor Tax, Shu-Oi Chow, Roxanne Cadiz, Karina Pazaky, Paulette Barahona, Pamela Ajuyah, Peter Trebilcock, Angela Malquori, Kate Gunther, Anica Avila, Doo Young Yun, Stephanie Alfred, Anjana Gopalakrishnan, Alvin Kamili, Marie Wong, Mark J. Cowley, Sophie Jessop, Loretta M. S. Lau, Toby N. Trahair, David S. Ziegler, Jamie I. Fletcher, Andrew J. Gifford, Maria Tsoli, Glenn M. Marshall, Michelle Haber, Vanessa Tyrrell, Timothy W. Failes, Greg M. Arndt, Richard B. Lock, Paul G. Ekert, M. Emmy M. Dolman

Summary: One-third of pediatric cancer patients enrolled in precision medicine programs do not receive therapeutic recommendations from molecular profiling. In order to find potential strategies for treating high-risk pediatric patients, a study conducted in vitro screening of 125 patient-derived samples against a library of 126 anticancer drugs. The results showed that high-throughput drug screening (HTS) can identify effective biomarker-driven therapeutic strategies for high-risk pediatric cancers.

CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

Lei Zhai, Anushree Balachandran, Rebecca Larkin, Janith A. Seneviratne, Sylvia A. Chung, Amit Lalwani, Shoma Tsubota, Dominik Beck, Kenji Kadomatsu, Anneleen Beckers, Kaat Durink, Katleen De Preter, Frank Speleman, Michelle Haber, Murray D. Norris, Alexander Swarbrick, Belamy B. Cheung, Glenn M. Marshall, Daniel R. Carter

Summary: Mitotic dysregulation is identified as a hallmark of tumor initiation in neuroblastoma and can be targeted by a combination therapy of antimitotic and pro-apoptotic compounds, leading to selective cell death in MYCN-driven neuroblastoma cell lines.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Health Care Sciences & Services

Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial

Rebecca Daly, Kate Hetherington, Emily Hazell, Bethany R. Wadling, Vanessa Tyrrell, Katherine M. Tucker, Glenn M. Marshall, David S. Ziegler, Loretta Lau, Toby N. Trahair, Tracey A. O'Brien, Kiri Collins, Andrew J. Gifford, Michelle Haber, Mark Pinese, David Malkin, Mark J. Cowley, Jonathan Karpelowsky, Donna Drew, Chris Jacobs, Claire E. Wakefield

Summary: Precision medicine programs aim to identify personalized treatments for children with cancer, but the various professional groups involved in delivering these programs are understudied. This study explored the experiences of professionals involved in Australia's first precision medicine trial for children with poor-prognosis cancer. The professionals expressed both complexity in their roles and positive views about the impact of precision medicine on their profession.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Meeting Abstract Oncology

True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention

Nadine Azzam, Nicole Melong, Lissandra Tuzi, Lisa Pinto, Jamie I. Fletcher, Alvin Kamili, Biljana Dumevska, Loretta Lau, Jennifer A. Chan, Donna L. Senger, Stephanie A. Grover, Michelle Haber, David Malkin, Jason N. Berman

CANCER RESEARCH (2023)

No Data Available